Anti-Nidogen-1 Neutralizing Antibody: Potential Treatment for Hepatocellular Carcinoma

The University of Hong Kong Background

Hepatocellular Carcinoma (HCC): ~75% of liver cancer
~50% of extrahepatic HCC patients have metastasis in lung
Estimated global incidence rate of liver cancer: 9.3/100k people / year
Mortality rate: 8.5
Need a solution to reduce the growth of HCC and minimize metastasis

Technology Overview

Nidogen-1 specific antibody
Good for neutralizing/blocking the functions of NID1 in liver cancer cell aggressive properties, tumor formation and metastasis


Research Tool for treatment of hepatocellular carcinoma


Anti-nidogen-1 antibody is ready to delivery for researchers
Developing treatment regime using anti-nidogen-1 antibody for liver cancer

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More